Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls

2026-07-16
SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls

Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220

2026-07-15
Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $235 to $220.

ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health

2026-07-15
Discover how the Best Dividend Stocks screen identifies sustainable payers like ResMed (RMD), combining high dividend ratings with strong profitability and health ratings for long-term stability.

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

2026-07-14
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Citigroup Downgrades ResMed (RMD)

2026-07-13

Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday

2026-07-13
Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.

Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235

2026-07-13
Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.

Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care

2026-07-10
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.

Jefferies Maintains Hold on ResMed, Lowers Price Target to $225

2026-07-10
Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price target from $240 to $225.

ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health

2026-07-10
ResMed (NYSE:RMD) has agreed to divest its MatrixCare business to a private equity buyer. The deal centers on refocusing the company around its sleep and respiratory health technologies and connected care platform. The transaction reflects a move away from post acute care software toward ResMed's core medical device and digital health operations. For investors watching ResMed, the exit from MatrixCare marks a clear effort to tighten the company’s focus on sleep apnea, respiratory care...